OCS
Oculis Holding AG
NASDAQ · Healthcare · Biotechnology · CH
$12.17
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 243.0K | — | 686.0K | — | — |
| Cost of Revenue | 157.4K | — | 52.1M | — | — |
| Gross Profit | 85.6K | — | (51.4M) | — | — |
| Operating Expenses | |||||
| R&D Expense | 56.9M | 54.5M | 52.1M | 29.2M | 22.2M |
| SG&A Expense | 29.7M | 24.6M | 21.8M | 14.7M | 6.7M |
| General & Admin Expense | 14.0M | — | 21.8M | 14.7M | 6.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 736.0K | — | (52.1M) | 36.7M | 3.4M |
| Total Operating Expenses | 87.3M | 79.1M | 21.8M | 80.7M | 32.4M |
| Cost and Expenses | 87.4M | 79.1M | 73.9M | 80.7M | 32.4M |
| Operating Income (EBIT) | (87.2M) | (79.1M) | (73.2M) | (80.7M) | (32.4M) |
| Non-Operating | |||||
| Interest Income | 1.8M | 1.7M | 2.2M | 1.6M | 126.0K |
| Interest Expense | 927.5K | 795.5K | 639.0K | 1.5M | 6.4M |
| Net Interest Income | 903.6K | 894.9K | 1.5M | 126.9K | (6.3M) |
| Other Non-Op Income/Expense | 7.3M | (15.5M) | (12.7M) | (8.0M) | (6.3M) |
| Non-Operating Income (excl Interest) | (8.2M) | 14.7M | 12.7M | 6.7M | (175.0K) |
| EBT (Pre-Tax Income) | (79.9M) | (94.7M) | (85.9M) | (88.7M) | (38.6M) |
| Income Tax Expense | (261.8K) | 177.6K | (160.0K) | 107.0K | 55.0K |
| Bottom Line | |||||
| Net Income | (79.7M) | (94.5M) | (85.8M) | (88.8M) | (38.7M) |
| Earnings from Cont. Ops | (79.7M) | (94.9M) | (85.8M) | (88.8M) | (38.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (79.7M) | (94.5M) | (85.8M) | (88.8M) | (38.7M) |
| Per Share | |||||
| Basic EPS | ($1.40) | ($1.81) | ($2.12) | ($2.97) | ($1.18) |
| Diluted EPS | ($1.40) | ($1.81) | ($2.12) | ($2.97) | ($1.18) |
| Revenue Per Share | $0.00 | $0.00 | $0.02 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 61.3M | 52.4M | 40.4M | 29.9M | 32.7M |
| Diluted Shares Outstanding | 61.3M | 52.4M | 40.4M | 29.9M | 32.7M |
| Profitability Metrics | |||||
| EBITDA | (78.5M) | (93.4M) | (85.5M) | (87.1M) | (31.9M) |
| D&A | 487.4K | 521.5K | 406.0K | 287.0K | 299.0K |
| EBIT | (79.0M) | (93.9M) | (85.9M) | (87.4M) | (32.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026